Search Within

Eric J Sherman

Formats
  1. Meeting Abstract (186)
  2. Journal Article (140)
  3. Review (6)
  4. Correspondence (3)
  5. Editorial (3)
  6. Research Letter (2)
  7. Book Section (1)
  8. Guidelines (1)
Groups
  1. Department of Medicine (342)
  2. Head and Neck Service (342)
  3. Solid Tumor Oncology Division (342)
  4. Radiation Oncology, Department of (202)
  5. Surgery (169)
  6. Survivorship Research (158)

More Groups

People
  1. Nancy Lee (198)
  2. Nadeem Riaz (147)
  3. David Pfister (126)
  4. Sean McBride (111)
  5. Richard Wong (108)
  6. Alan Ho (86)

More People

Years
  1. 2025 (3)
  2. 2024 (36)
  3. 2023 (24)
  4. 2022 (29)
  5. 2021 (21)
  6. 2020 (38)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (94)
  2. Journal of Clinical Oncology (83)
  3. Annals of Oncology (19)
  4. Cancer (16)
  5. Head & Neck (16)
  6. Oral Oncology (8)

More Publications

Publishers
  1. Elsevier Inc. (110)
  2. American Society of Clinical Oncology (85)
  3. Wiley Blackwell (26)
  4. Oxford University Press (25)
  5. John Wiley & Sons, Inc. (16)
  6. American Medical Association (11)

More Publishers

Results (342)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nomogram to predict risk of early mortality following definitive or adjuvant radiation and systemic therapy for head and neck cancer
    Meeting Abstract

    Raab, G. T.; Yu, Y.; Sherman, E.; Wong, R. J.; Mell, L. K.; Lee, N. Y.; Zakeri, K.
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaïve, RET-mutant medullary thyroid cancer
    Meeting Abstract

    Hadoux, J.; Elisei, R.; Brose, M. S.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Dose expansion results of the bifunctional EGFR/TGFb inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J.; Zandberg, D. P.; Wong, D. J.; Yilmaz, E.; Sherman, E. J.; Calvo, A. H.; Sacco, A. G.; Bohr, D.; Reiners, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Combined patient specific tumor and HPV sequencing enables high sensitivity detection of ctDNA in HPV-associated oropharyngeal carcinoma patients
    Meeting Abstract

    Diplas, B. H.; Brown, D.; Pei, X.; Graybill, C.; Novaj, A.; Korn, W. M.; Daber, R.; Humm, J.; Shukla-Dave, A.; Schoder, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in advanced salivary gland cancer: A phase 2 trial
    Journal Article

    Vos, J. L.; Burman, B.; Jain, S.; Fitzgerald, C. W. R.; Sherman, E. J.; Dunn, L. A.; Fetten, J. V.; Michel, L. S.; Kriplani, A.; Ng, K. K.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer
    Journal Article

    Hadoux, J.; Elisei, R.; Brose, M. S.; Hoff, A. O.; Robinson, B. G.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer
    Meeting Abstract

    Abdelhamid Ahmed, A. H.; Russell, M. D.; Kyriazidis, N.; Silver Karcioglu, A.; Sherman, E. J.; Ho, A. L.; Fagin, J. A.; Wong, R. J.; Busaidy, N. L.; Zafereo, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer
    Meeting Abstract

    Desilets, A.; Pfister, D. G.; Wong, W.; Sherman, E. J.; Fetten, J. V.; Hung, K. W.; Dunn, L.; Ho, A. L.; Michel, L. S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Mohamadpour, M.; Sherman, E. J.; Kriplani, A.; Fetten, J. V.; Dunn, L.; Michel, L. S.; Hung, K. W.; Baxi, S. S.; McDonald, E.; Conybeare, R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
    Meeting Abstract

    Hanna, G. J.; Kaczmar, J. M.; Zandberg, D. P.; Wong, D. J. L.; Yilmaz, E.; Sherman, E. J.; Hernando-Calvo, A.; Sacco, A. G.; Chung, C. H.; Bohr, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save